Gene Modifiers of Cystic Fibrosis Lung Disease

StatusActive, Not Recruiting
PhaseNot specified
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary and study completion dates: Jul 2026 to Jul 2027v26
  2. Primary and study completion dates: Jul 2024 to Jul 2026v25
  3. Primary and study completion dates: Jul 2023 to Jul 2024
    • Eligibility criteria expanded, about 14 words
    • Publications: 48 to 51
    v24
  4. Primary and study completion dates: Jul 2022 to Jul 2023
    • Publications: 32 to 48
    v23
  5. Primary and study completion dates: Jul 2021 to Jul 2022v22
Show 20 earlier versionsHide 20 earlier versions
  1. Study site revisedv21
  2. Primary and study completion dates: Jul 2019 to Jul 2021v20
  3. Primary and study completion dates: Jul 2018 to Jul 2019
    • Publications: 20 to 32
    v19
  4. Collaborators expanded, about 7 wordsv18
  5. Primary and study completion dates: Jul 2017 to Jul 2018v17
  6. Primary and study completion dates: Jul 2016 to Jul 2017v16
  7. Re-verified, no change to tracked fieldsv15
  8. Primary and study completion dates: Jul 2015 to Jul 2016v14
  9. Re-verified, no change to tracked fieldsv13
  10. Trial status: Recruiting to Active, Not Recruiting
    • Site details revised
    v12
  11. Publications: 6 to 20v11
  12. Primary and study completion dates: Aug 2012 to Jul 2015v10
  13. Collaborators shortened, about 7 wordsv9
  14. Primary and study completion dates: Aug 2011 to Aug 2012
    • Publications: 5 to 6
    v8
  15. Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI) to University of North Carolina, Chapel Hill
    • Collaborators expanded, about 7 words
    • Publications: 1 to 5
    v7
  16. Re-verified, no change to tracked fieldsv6
  17. Study title revisedv5
  18. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    v4
  19. Trial status: Active, Not Recruiting to Not Yet Recruitingv3 Show 4 more changesShow less
    • Enrollment target: 600
    • Primary completion date: Aug 2011
    • Study completion date: Aug 2006 to Aug 2011
    • Eligibility criteria expanded, about 2 words
  20. Study Status, Referencesv2
  1. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to examine genetic modifiers of the severity of cystic fibrosis lung disease.
Trial Details
NCT Number NCT00037765
Lead Sponsor University of North Carolina, Chapel Hill
Collaborators: National Heart, Lung, and Blood Institute (NHLBI)
Conditions
(from sponsor)		 Cystic Fibrosis, Lung Diseases
Related terms Cystic Fibrosis, Lung Diseases
Enrollment 600 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov